Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  talazoparib
Find trials that include:  Any drugs shown
Results 1-9 of 9 for your search:
Start Over
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 673-301, NCI-2014-00659, U1111-1155-7579, NCT01945775
Talazoparib in Treating Patients with Advanced Solid Tumors and BRCA Mutations
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9510, NCI-2013-02371, 09-25-0099, 140015, P131220, P9510_A08PAMDREVW01, 14-C-0015, NCT01989546
Talazoparib and Temozolomide in Treating Younger Patients with Refractory or Recurrent Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: ADVL1411, NCI-2014-00804, NCT02116777
Talazoparib before Standard Therapy in Treating Patients with Invasive, BRCA-Mutated Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0045, NCI-2015-00335, NCT02282345
Talazoparib in Treating Patients with BRCA1 and BRCA2 Wild-Type, Metastatic or Recurrent, Triple-Negative or HER2-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BRS0050, NCI-2015-00036, 350, NCT02401347
Talazoparib, Carboplatin, and Paclitaxel in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9782, NCI-2014-02474, NCI 9782, NCT02317874
Talazoparib, Carboplatin, and Paclitaxel in Treating Patients with Advanced Solid Tumors and BRCA Mutations or Triple-Negative Metastatic Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CC #14955, NCI-2015-00713, 130847, 14955, NCT02358200
BMN-673 and Irinotecan Hydrochloride with or without Temozolomide in Treating Younger Patients with Refractory or Recurrent Solid Malignancies
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 25
Trial IDs: BMNIRN, NCI-2015-00255, NCI-2015-00215, NCT02392793
Talazoparib in Treating Patients with Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PJC-022, NCI-2015-01641, 9942, NCT02567396
Start Over